Brought to you by 
Celgene, Pharmion restructure 2001 thalidomide deal
16 Nov 2021
Executive Summary
As a revision to their 2001 Thalomid (thalidomide) deal, Pharmion (cancer therapeutics) and its partner, small-molecule immunotherapeutics developer Celgene, have signed a new three-year-agreement for worldwide development of the candidate--which is now pending FDA approval in the US--for multiple myeloma.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene, Pharmion restructure 2001 thalidomide deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice